# Chiesi Pharmaceuticals

> Chiesi Pharmaceuticals is a VC fund in Parma backing Medical and Health Care. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Parma, Italy
- Total investments: 2
- Last investment: Jun 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/chiesi-group
- Website: https://www.chiesi.com/en/
- Facebook: https://www.facebook.com/chiesifarmaceutici/

Chiesi Pharmaceuticals is a VC fund in Parma focused on Medical and Health Care. Chiesi Pharmaceuticals provides research, development, production, and marketing of medicines for respiratory, neonatology, rare diseases. It was established in 1935 and is based in Parma, Emilia-Romagna.

## Contacts

5 contacts available for Chiesi Pharmaceuticals. Shizune tracks 8 team members at Chiesi Pharmaceuticals. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/chiesi-pharmaceuticals?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 100% |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Genetics | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Private Equity | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 1 | 50% |
| The Netherlands | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alberto Chiesi | Chairman | 0 | — |
| Danilo Piroli | Director | 0 | — |
| Diego Ardigò | Global Rare Diseases, Research & Development Head | 0 | — |
| Paolo Chiesi | Vice Chairman | 0 | — |
| Raffaella Monno | Head of Real World Evidence, R&D Global Clinical Development | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyclica | Cyclica is the partner of choice for data-driven drug discovery. The software developed by the company uses biophysics and artificial intelligence (AI) to improve drug discovery practices by generating a list of putative ligand-protein interactions, allowing health institutions to prioritize lead candidates, elucidate adverse effects, andunderstand repurposing opportunities. | $16.9M | Series B | Jun 24, 2020 |  |
| UniQure | uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeuticprotein or restoring the expression of a missing protein through a single administration.Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease.We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations. | $58M | Private Equity | Jul 09, 2013 |  |

2 of 2 investments shown.

## Co-investors
- Coller Capital — VC Fund, 1 deal together
- [Drive Capital](https://shizune.co/investors/profile/drive-capital) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together
- [GreenSky Ventures](https://shizune.co/investors/profile/greensky-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chiesi Pharmaceuticals invest in?

Chiesi Pharmaceuticals invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Chiesi Pharmaceuticals?

Public channels for Chiesi Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Chiesi Pharmaceuticals?

The team at Chiesi Pharmaceuticals includes Alberto Chiesi (Chairman), Danilo Piroli (Director) and Diego Ardigò (Global Rare Diseases, Research & Development Head), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co